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Summary
Significant cardiovascular morbidity and mortality exists in chronic obstructive pulmonary
disease (COPD). Arterial stiffness is raised in COPD and may be a mechanistic link. Non-
invasive assessment of arterial stiffness has the potential to be a surrogate outcome measure,
although no reproducibility data exists in COPD patients.
Two studies (23 and 33 COPD patients) were undertaken to 1) assess the Vicorder reproduc-
ibility of carotid-femoral pulse wave velocity and Augmentation index in COPD; 2) compare it
to SphygmoCor; and 3) assess the contribution of lung hyperinflation to measurement vari-
ability.
There were excellent correlations and good agreement between repeat Vicorder measure-
ments for carotid-femoral pulse wave velocity (r Z 0.96 (p < 0.001); mean difference
SD Z 0.03  0.36 m/s (p Z 0.65); co-efficient of reproducibility Z 4.02%; limits of
agreement Z 0.68e0.75 m/s). Augmentation index significantly correlated (r Z 0.736
(p < 0.001); mean difference SD Z 0.72  4.86% (p Z 0.48), however limits of agreement
were only 10.42e9.02%, with co-efficient of reproducibility of 27.93%. Comparing devices,
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Vicorder values were lower but there was satisfactory agreement. There were no correlation
between lung hyperinflation (as measured by residual volume percent predicted, total lung
capacity percent predicted or the ratio of inspiratory capacity to residual volume) and vari-
ability of measurements in either study.
In COPD, measurement of carotid-femoral pulse wave velocity is highly reproducible, not
affected by lung hyperinflation and suitable as a surrogate endpoint in research studies.
Day-to-day variation in augmentation index highlights the importance of such studies prior
to the planning and undertaking of clinical COPD research.
ª 2013 Elsevier Ltd.
Introduction
Significant cardiovascular morbidity and mortality exists in
chronic obstructive pulmonary disease (COPD) which is
independent of shared risk factors such as smoking [1].
Different mechanisms linking these two common conditions
have been proposed, including arterial stiffness, a surrogate
shown to be an independent predictor of cardiovascular dis-
ease in a number of other chronic inflammatory conditions
[2,3]. A spill over of inflammation from the pulmonary to the
systemic circulation whose down-stream effects result in
raised arterial stiffness could provide the mechanistic link
between COPD and cardiovascular morbidity and mortality.
Similarly neuro-humoral activation of the sympathetic ner-
vous system as a result of lung hyperinflation may be a
contributory factor [4].
Carotid-femoral pulse wave velocity (cfPWV) and
Augmentation Index (AI) are non-invasive measures by
which arterial stiffness can be measured. The arterial
pressure wave is formed by a composite of ventricular
contraction and a reflected wave that arrives back early in
stiff arteries, adding to the forward wave, augmenting
systolic pressure and forming the second systolic peak. This
phenomenon can be quantified as the AI, defined as the
difference between the 2 systolic peaks expressed as a
percentage of the pulse pressure. It is derived from pulse
wave analysis (PWA) where peripheral artery waveforms
are acquired and validated transfer functions are used to
derive values of the Aortic AI. cfPWV is estimated by
measuring the transit time of the pulse wave between two
pulse points [5].
A number of commercial devices exist for arterial stiff-
ness measurement although at present no consensus exists
as to which is the most accurate or reproducible. A novel
relatively operator-independent device is now available
which has potential advantages for screening programmes
and use in intervention studies. It has compared favourably
with the more established SphygmoCor device, considered
by some to be the gold standard, in normal individuals, and
those undergoing routine angiography [6,7]. Although
CfPWV has been found to be raised in COPD and related to
disease severity and other studies report on pulse wave
analysis (PWA) [8,9], no data exist on the reproducibility of
these devices in COPD patients, who due to their lung hy-
perinflation may have large intra-thoracic pressure swings
with potentially significant breath-to-breath variation in
the pulse wave. Such information is integral to the design
and powering of longitudinal intervention studies.
The aim of this study was: 1) To assess the reproduc-
ibility of the Vicorder Device in measuring cfPWV and AI in
COPD patients; 2) to compare the measurements with those
of the SphygmoCor device in a second separate cohort of
COPD patients and 3) furthermore assess the contribution
of hyperinflation to the reproducibility of arterial stiffness
measurements.
Materials and methods
Patients
Patients were prospectively enrolled from an existing COPD
and cardiovascular disease database held at a university
teaching hospital between October 2011 and August 2012.
All patients were over 40 years of age, with a smoking
history of at least 15 pack-years, and spirometric evidence
of COPD according to ATS/ERS criteria. They were clinically
stable with no history or recent exacerbations or long term
oxygen therapy use. Demographic data and a full medical
and therapeutic history were collected on all participants.
Furthermore, lung function (spirometry and body plethys-
mograph) was performed in all participants. For the
Vicorder reproducibility study (VRS) 23 consecutive pa-
tients had repeat measurements of cfPWV and PWA per-
formed within 2 weeks of each other. For the Comparison
study (VCS) with SphygmoCor a separate cohort of 33
consecutive COPD patients had cfPWV and PWA measure-
ments performed on the same day with both devices. No
patients in the VRS cohort were included in the VCS cohort.
The study received a favourable review by the local
research ethics committee and written informed consent
was obtained from all patients.
Measurement techniques
Arterial stiffness
All measurements were performed by a single investigator
with 18 months experience in arterial stiffness measure-
ments (IS). IS was blinded to the previous results in the VRS
but not the VCS since measures were collected on the same
day for the latter study.
In the VCS the same brachial blood pressure was used to
calibrate both devices. The SphygmoCor measurements
were performed first, followed by the Vicorder measure-
ments, in all cases.
All arterial stiffness measurements were in a tempera-
ture controlled room with the patient rested for 15 min in a
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supine position and awake. Patients were required to
refrain from vasoactive medications for 2 h, bronchodilator
therapy for 6 h, alcohol for 10 h and smoking and caffeine
for 3 h prior to the measurements. All measurements were
repeated 3 times and the mean value was derived.
Vicorder measurements
Pulse wave velocity
Measurements were obtained by placing a 10 cm wide blood
pressure cuff around the upper right thigh for measurement
of the femoral pulse and a 3 cm partial cuff around the neck
at the level of the carotid artery. The path-length was
calculated according manufacturers instructions, from the
suprasternal notch to a defined point on the upper part of
the femoral Cuff. The cuffs were inflated simultaneously
to 65 mmHg and 2 high quality waveforms were simulta-
neously recorded for 3 s using a volume displacement
method. The foot-to-foot transit time (TT) was measured as
described previously [7] and values for cfPWV were derived
automatically.
Pulse wave analysis
Two brachial blood pressure readings were obtained using a
manual sphygmomanometer used for calibrating peripheral
waveforms and immediately afterwards a brachial pressure
wave trace was digitally computed by the Vicorder with the
cuff statically inflated to 70 mmHg using a volume displace-
ment technique. A previously described brachial-to-aortic
transfer function was then applied by the Vicorder software
[10] to calculate thewaveform and values for central BP. The
first and second central systolic peaks were automatically
identified by the software and used to calculate the
Augmentation index (difference in amplitude between first
and second systolic peak/pulse pressure  100).
SphygmoCor measurements
Pulse wave velocity
The SphygmoCor device (soft-ware version CvMS V9, Atcor
Medical) employs applanation tonometry (Miller In-
struments Inc. Houston TX, USA) to sequentially record ECG
gated carotid and femoral artery waveforms. TT was
calculated by the system software by the intersecting
tangent method, using the R wave of a simultaneously
recorded ECG as a reference frame. The path length was
calculated according to the guidelines of the ARTERY soci-
ety and manufacturers recommendation (supra-sternal
notch to femoral artery recording site e suprasternal notch
to carotid artery recording site) and the automated soft-
ware derived the cfPWV [11].
Pulse wave analysis
Two brachial blood pressure readings were obtained using a
manual sphygmomanometer, used for calibrating radial
arterywaveforms, whichwere recorded using the same high-
fidelity applanation tonometer described above. A previ-
ously validated radial-aortic transfer function was then
automatically applied to the waveform to derive central BP
[12]. The first and second central systolic peaks were auto-
matically identifiedby the softwareandused to calculate the
Augmentation index (difference in amplitude between first
and second systolic peak/pulse pressure  100).
Pulmonary function
Pulmonary function testing (spirometry and body plethys-
mography) was conducted by experienced respiratory
therapists/technicians using automated pulmonary func-
tion testing equipment (CPL PFT, United states and ZAN500,
Germany) in keeping with current recommended standards
[13,14].
Statistical analysis
Statistical analysis was performed using SPSS 21.0 for Mac
(SPSS Inc., Chicago, Illinois, USA). The distribution of the
data was assessed visually. Continuous variables were
expressed as mean  SD for parametric variables and me-
dian (interquartile range) for non-parametric variables.
Agreement between repeated Vicorder values in the case of
the VRS, and SphygmoCor and Vicorder values in the case of
the VCS for both cfPWV and AI were analysed with a stu-
dent’s paired t-test with further analysis performed using
BlandeAltman Plots [15]. Pearson’s correlation co-efficient
was used to assess the strength of correlation between
these values as well as the contribution of hyperinflation to
the variability of PWV and AI. All analyses were 2 sided and
a probability of less than 0.05 was considered significant.
Results
Vicorder reproducibility study
Demographic Parameters for VRS are shown in Table 1.
Haemodynamic parameters for both VRS visits are shown in
Table 2. Good quality waveforms were available for all 23
patients. There was a strong significant correlation between
repeat Vicorder Measurements with respect to cfPWV
(r Z 0.96 p < 0.001). The mean difference  SD between
repeated cfPWV measurements was 0.03  0.36 m/s
(p Z 0.65) with a co-efficient of reproducibility (COR) of
4.02% and limits of agreement (LOA) of 0.68e0.75 m/s
(Fig. 1). Repeat path length and pulse transit time mea-
surements were similar and strongly correlated with CORs of
3.6% and 4.77% respectively (Table 3). The repeat AI mea-
surements were also strongly and significantly correlated
(r Z 0.736 p < 0.001) with mean difference SD of
0.72  4.86% (p Z 0.48), however LOA were only
10.42e9.02%, with COR of 27.93% (Fig. 2).
Vicorder comparison study
Demographic parameters and haemodynamic parameters
for VCS are shown in Tables 1 and 2 respectively. Good
quality waveforms were achieved for AI, however, 3 pa-
tients were unable to record SphygmoCor cfPWV readings
due to a variable heart rate. There were statistically sig-
nificant differences in the mean differences of cfPWV and
AI between devices. Path length and pulse transit time
differences were also significantly different between de-
vices although strongly correlated (Table 3). The Vicorder
device recorded lower values of both cfPWV and AI readings
(mean difference  SD 0.64  1.00 m/s p Z 0.002 and
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mean difference  SD 4.53  7.8 p Z 0.002, respec-
tively). There was, however, a strong linear relationship
between Vicorder and SphygmoCor for cfPWV
(r Z 0.76 P < 0.001) and AI (r Z 0.56, p Z 0.01) and
BlandeAltman plots confirmed satisfactory agreement
(Figs. 3 and 4).
The contribution of lung hyperinflation to
reproducibility
In order to assess the contribution of lung hyperinflation to
the reproducibility of arterial stiffness correlations were
performed between RV%, TLC% and IC/TLC and the differ-
ence between repeated measurements of AI and PWV.
There was no significant correlation between the extent of
lung hyperinflation and the variability of PWV or AI mea-
surements in either the VRS or VCS (Table 4).
Discussion
The contribution of arterial stiffness to the cardiovascular
morbidity in COPD is a topic of considerable interest [4,8].
This is the first study to report reproducibility of Vicorder
measures of arterial stiffness and, furthermore, how they
compare to SphygmoCor measurements in patients with
COPD. The main finding of our study is that PWV measured
by the Vicorder device is highly reproducible in COPD pa-
tients. The Vicorder reproducibility achieved in this study
for PWV is better than some other published results
including those in children [16,17] and studies employing
different commercially available devices [18,19]. The sec-
ond finding is that the reproducibility of PWV or Augmen-
tation index does not appear to be affected by lung
hyperinflation and thirdly, although significant statistical
differences exist between the Vicorder and SphygmoCor
devices the BlandeAltman plot showed satisfactory agree-
ment and the values showed good linear agreement in this
COPD cohort.
It is generally agreed that external factors impact on
pulse wave velocity. A potential limitation of this study is
that we are unable to gauge the impact of changes in
oxygenation, known to affect PWV and AI, since blood gas
sampling was not performed [20]. However efforts had
been made to minimise its occurrence through the
recruitment of only clinically stable patients who did not
require any form of oxygen therapy as well as the imple-
mentation of existing recommendations to standardize
Table 1 Demographic characteristics for Vicorder repro-
ducibility study (VRS) and Vicorder comparison study (VCS).
VRS
Mean  SD or
median (25e75%)
VCS
Mean  SD
Number of
participants
23 33
Age (years) 65.9  7.9 67.5  8.2
FEV1% 50.1  18.9 52.9  19.0
FEV/FVC 45.9  15.4 45.6  13.2
RV% 163.9  52.8 157.5  47.7
TLC% 113.7  22.6 116.2  39.2
IC/TLC 33.4  12.2 33.5  9.4
BMI (kg/m2) 25.9  5.8 25.0  8.7
Pack year history 50(40e120) 56.9  38.1
Current smoker 4/23 5/33
Males:females 12:11 19:14
Statin 12/23 15/33
Aspirin 8/23 8/33
Anti-hypertensive 11/23 13/33
ICS 1/23 3/33
SABA 22/23 27/33
LABA 1/23 2/33
ICS/LABA 19/23 20/33
LAMA 21/23 26/33
Methylxanthines 3/23 6/33
VRS; Vicorder reproducibility study: VCS; Vicorder comparison
study: FEV1%; forced expiratory volume in one second per cent
predicted of normal value: FEV/FVC; ratio of the forced expi-
ratory volume/forced vital capacity: RV%; residual volume per
cent predicted of normal value: IC/TLC; ratio of inspiratory
capacity to total lung capacity: TLC%; total lung capacity per
cent predicted of normal value BMI; body mass index: SBP;
systolic blood pressure: DBP; diastolic blood pressure: ICS;
inhaled corticosteroid: SABA; short-acting beta-agonist: LABA;
long-acting beta-agonist: LAMA; long-acting muscarinic antag-
onist.
Table 2 Haemodynamic parameters for the Vicorder reproducibility study (VRS) and the Vicorder comparison study (VCS).
VRS VCS
N 23 33
Visit 1 Visit 2 Vicorder SphygmoCor
Heart rate (beats/min) 72.6  11.5 73.1  10.2 74.1  11.6 75.3  11.8
Brachial SBP (mmHg) 138.5  13.9 136.8  15.8 129.1  16.5
Brachial DBP (mmHg) 75.6  6.3 74.3  8.1 69.6  11.7
MAP (mmHg) 102.0  9.0 101.3  10.2 90  11.3
Central SBP (mmHg) 130.9  13.7 130.8  14.5 119.2  24.7 115.9  15.2
Central DBP (mmHg) 75.0  6.9 74.1  7.5 69.5  10.9 70.6  11.7
PWV (m/s) 8.94  1.2 8.97  1.2 8.93  1.3 9.5  1.5
AI (%) 17.8  6.7 17.1  6.7 21.9  8.1 26.5  8.6
VRS; Vicorder reproducibility study: VCS; Vicorder comparison study: SBP; systolic blood pressure: DBP; diastolic blood pressure: MAP;
mean arterial blood pressure: PWV; pulse wave velocity: AI; augmentation index.
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conditions [21]. The value derived for PWV is also known to
depend on the site of measurement, the algorithm used for
timing of the pressure wave transit (TT) and the method
employed for calculating path length.
The predictive value of PWV is dependent on the site of
measurement. In end-stage renal disease whereas the
upper and lower limb PWV have no predictive value [22],
the aorto-iliac pathway measured via carotid-femoral PWV
is a predictor of cardiovascular and all cause mortality [23].
It is the carotid-femoral PWV (cfPWV) that is thought to be
the most clinically relevant and robust measurement and it
has been shown to be an independent predictor of coronary
artery disease in the general population including the
elderly [24e26] and it is at present considered the gold
standard [5]. In line with the ARTERY society guidelines
[11], both studies contained within this manuscript exclu-
sively measured cfPWV.
The impact of the algorithm used to calculate the transit
time has been investigated with different commercially
available devices with conflicting results [27,28], some
attributing differences to the algorithm whereas others
identify path length measurements as the main driver for
differences between devices. This however is the first study
to look at the contribution of lung hyperinflation to mea-
surement variability. Lung hyperinflation can be defined
according the residual volume with RV% >120 considered
abnormal. The patients enrolled in the two studies had had
a substantial degree of lung hyperinflation, with mean RV%
values of 163.9% and 157.5% respectively, but no significant
correlation between the extent of lung hyperinflation and
variability of arterial stiffness measurements was identified
in either of the 2 studies regardless of which parameter for
measuring lung hyperinflation was adopted (RV, TLC or IC/
TLC). Hence our results are closely aligned with other
studies that compare Vicorder and SphygmoCor, demon-
strating that methodological differences in the measure-
ment of path length are contributing to the differences
seen in PWV values between these two devices, although
significant differences were demonstrated there was good
linear agreement between devices, and there was a bias
towards lower values with the Vicorder [7,29].
Measurement of the path length can result in a disparity
between values derived for PWV of up to 30% [30]. We have
shown that the path length is also the main driver for the
Figure 1 a) Scatterplot of repeat Vicorder Pulse Wave Velocity (PWV) measurements. Solid line: line of equality; dotted line:
linear regression line. b) BlandeAltman plot of the differences between Vicorder PWV measurements. Solid line: mean value;
dotted lines: Limits of Agreement (mean  2SDs).
Table 3 Mean transit time and path length data.
Vicorder reproducibility study
Visit 1
Mean  SD
Visit 2
Mean  SD
Mean difference SD Correlation
Path length (cm) 66.4  5.5 66.7  5.0 0.3  2.4 (p Z 0.61) 0.90 (p < 0.001)
Transit time (ms) 77.1  11.9 76.2  11.0 0.96  3.7 (p Z 0.23) 0.95 (p < 0.001)
Vicorder comparison study
Vicorder
Mean  SD
SphygmoCor
Mean  SD
Mean difference SD Correlation
Path length (cm) 66.6  5.3 47.9  4.0 18.8  3.7 (p < 0.001) 0.72 (p < 0.001)
Transit time (ms) 75.7  11.4 50.6  8.5 25.1  9.0 (p < 0.001) 0.63 (p Z 0.01)
SD; standard deviation.
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variability of PWV measurements in both studies. In the VRS
the COR for path length accounts for most of the variability
seen in pulse transit time. In the VCS the situation is further
complicated by different manufacturers recommending
different methodologies to calculate the path length, as
seen with the Vicorder and SphygmoCor devices. From a
methodological perspective the precision of any particular
measured distance is dependent on the accuracy of iden-
tifying the measurement site and the precision of the tape
measure. For those techniques that involve 2 measure-
ments, as in the case of the SphygmoCor, the error is made
twice, is cumulative, and in certain circumstances may be
larger than the discrepancy between different path length
techniques [31]. It is currently not clear which path length
is the most appropriate or which device is the more accu-
rate since validation of pulse wave velocity with invasive
studies has proven difficult, a problem acknowledged by
the published guidelines on validation of haemodynamic
non-invasive measurement devices [11]. The difficulty ari-
ses since the invasive measure chosen typically equates to
the PWV within the aorta and does not take into account
the additive effect that may arise from the iliac and carotid
vessels [32,33]. This lack of a comparable invasive measure
for PWV as well as AI is a resultant limitation of this study.
Figure 2 a) Scatterplot of repeat Vicorder Augmentation Index (AI) measurements. Solid line: line of equality; dotted line: linear
regression line. b) BlandeAltman plot of the differences between Vicorder measurements. Solid line: mean value; dotted lines:
Limits of Agreement (mean  2SDs).
Figure 3 a) Scatterplot of Vicorder and SphygmoCor Pulse Wave Velocity (PWV). Solid line: line of equality; dotted line: linear
regression line. b) BlandeAltman plot of the differences between Vicorder SphygmoCor PWV. Solid line: mean value; dotted lines:
Limits of Agreement (mean  2SDs).
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Screening tools to establish whether a subject has raised
arterial stiffness require agreed normal ranges and a device
which is both accurate and reproducible. Although there
have been developments in this field [34], until an agreed
methodology for path length measurements and further
validation studies are available it seems the most likely use
of PWV will be in assessing the impact of particular in-
terventions within clinical trials. In this setting accuracy is
arguably less important than reproducibility; it not only
impacts on the sample size but the mean bias, derived from
such measures, is important for trial comparison in the
context of systematic reviews and metanalyses. Repro-
ducibility of a particular test is therefore paramount, and
the Vicorder device has shown itself to be a highly plausible
option in COPD studies looking to utilise cfPWV as a surro-
gate endpoint.
Augmentation Index is a measure of the augmentation of
central blood pressure in systole by reflected pressure
waves from the small peripheral arteries [5]. It is depen-
dent on ventricular ejection, the timing of reflected waves
(and hence PWV) and the extent of reflection (determined
by arterial tone). In the VRS although the BlandeAltman
plot showed reasonable agreement and the SD of differ-
ences were similar to previously published studies of
different devices [19], the larger LOA and COV associated
with AI and resultant loss of statistical power would require
far larger sample sizes to demonstrate any significant
treatment effects. However a limitation of this study is that
the repeat measurements were not performed on the same
day for the VRS which, given the number of factors that
contribute to augmentation, may have resulted in the dif-
ferences observed. The notion is supported by a study in
chronic kidney disease that looked at day to day variations
in AI which showed even greater variability in measures
with a mean difference (SD) of 2.6 (5.6) [35]. Furthermore,
validation studies, which are more feasible for PWA due to
the relative ease of acquiring invasive central blood pres-
sures, have demonstrated that the Vicorder device is ac-
curate. Vicorder measures of central blood pressure,
estimated using the same transfer function as AI, showed
better agreement with invasive measures than the Sphyg-
moCor and was highly correlated to the invasive measure
Figure 4 a) Scatterplot of Vicorder and SphygmoCor Augmentation Index (AI). Solid line: line of equality; dotted line: linear
regression line. b) BlandeAltman plot of the differences between Vicorder SphygmoCor AI. Solid line: mean value; dotted lines:
Limits of Agreement (mean  2SDs).
Table 4 Correlation between measures of lung hyperinflation and the variability of repeat AI and PWV measurements in the
Vicorder reproducibility study (VRS) and the Vicorder comparison study (VCS).
Difference between repeat haemodynamic measurements
Vicorder reproducibility study Vicorder comparison study
AI PWV AI PWV
Measures of lung hyperinflation RV% 0.34 (p Z 0.12) 0.20 (p Z 0.36) 0.10 (p Z 0.61) 0.22 (p Z 0.25)
TLC% 0.21 (p Z 0.35) 0.16 (p Z 0.47) 0.09 (p Z 0.63) 0.11 (p Z 0.59)
IC/TLC 0.16 (p Z 0.48) 0.32 (p Z 0.15) 0.11 (p Z 0.58) 0.34 (p Z 0.08)
AI; augmentation index: PWV; pulse wave velocity: RV%; residual volume per cent predicted of normal value: IC/TLC; ratio of inspiratory
capacity to total lung capacity: TLC%; total lung capacity per cent predicted of normal value.
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[6]. Despite this in COPD the utility of AI in the elderly re-
mains in question; although Janner et al. showed a signifi-
cant association between AI and COPD this was only for
males less than 60 years of age once mild cases had been
excluded [36].
In conclusion, this study highlights the highly reproduc-
ible nature of Vicorder PWV measurements in COPD
patients, including those with lung hyperinflation, which
offers a feasible alternative to traditional tonometry
techniques that is ideally suited for use as a surrogate
marker in intervention studies. The wide day-to-day vari-
ation in repeat AI measurements highlights the importance
of such calculations prior to the planning and undertaking
of clinical research in COPD.
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